66 related articles for article (PubMed ID: 27881177)
1. High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
Pourabdollah M; Bahmanyar M; Atenafu EG; Reece D; Hou J; Chang H
J Hematol Oncol; 2016 Nov; 9(1):123. PubMed ID: 27881177
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.
Holstein SA; McCarthy PL
Drugs; 2017 Apr; 77(5):505-520. PubMed ID: 28205024
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Malard F; Harousseau JL; Mohty M
Cancer Treat Rev; 2017 Jan; 52():41-47. PubMed ID: 27888768
[TBL] [Abstract][Full Text] [Related]
4. Sequencing of nontransplant treatments in multiple myeloma patients with active disease.
Yee AJ; Raje NS
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):495-503. PubMed ID: 27913521
[TBL] [Abstract][Full Text] [Related]
5. Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma.
Offidani M; Corvatta L; Bringhen S; Gentili S; Troia R; Maracci L; Larocca A; Gay F; Leoni P; Boccadoro M
Eur J Haematol; 2017 Mar; 98(3):289-295. PubMed ID: 27893171
[TBL] [Abstract][Full Text] [Related]
6. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.
Jones JR; Cairns DA; Gregory WM; Collett C; Pawlyn C; Sigsworth R; Striha A; Henderson R; Kaiser MF; Jenner M; Cook G; Russell NH; Williams C; Pratt G; Kishore B; Lindsay J; Drayson MT; Davies FE; Boyd KD; Owen RG; Jackson GH; Morgan GJ
Blood Cancer J; 2016 Dec; 6(12):e506. PubMed ID: 27935580
[TBL] [Abstract][Full Text] [Related]
7. Myeloma: management of the newly diagnosed high-risk patient.
Dispenzieri A
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):485-494. PubMed ID: 27913520
[TBL] [Abstract][Full Text] [Related]
8. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma.
Vo MC; Anh-NguyenThi T; Lee HJ; Nguyen-Pham TN; Jaya Lakshmi T; Jung SH; Kim HJ; Lee JJ
Exp Hematol; 2017 Feb; 46():48-55. PubMed ID: 27889516
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Multiple Myeloma in a Heart Transplant Recipient.
Xie L; Jozwik B; Weeks P; Buja LM; Brown R; Nathan S; Rajagopal K; Paruthi C; Kar B; Loyalka P; Rajapreyar I
Prog Transplant; 2017 Mar; 27(1):65-68. PubMed ID: 27885144
[TBL] [Abstract][Full Text] [Related]
12. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.
Bordini J; Galvan S; Ponzoni M; Bertilaccio MT; Chesi M; Bergsagel PL; Camaschella C; Campanella A
Leukemia; 2017 Apr; 31(4):967-970. PubMed ID: 27881873
[No Abstract] [Full Text] [Related]
13. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
14. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Borsi E; Mazzocchetti G; Dico AF; Vigliotta I; Martello M; Poletti A; Solli V; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Rizzello I; Cavo M; Terragna C
Clin Exp Med; 2023 Dec; 23(8):5227-5239. PubMed ID: 37815734
[TBL] [Abstract][Full Text] [Related]
15. Novel IKZF3 transcriptomic signature correlates with positive outcomes of skin cutaneous melanoma: A pan-cancer analysis.
Yang LK; Lin CX; Li SH; Liang JJ; Xiao LL; Xie GH; Liu HW; Liao X
Front Genet; 2022; 13():1036402. PubMed ID: 36353107
[TBL] [Abstract][Full Text] [Related]
16. Ikaros Proteins in Tumor: Current Perspectives and New Developments.
Xia R; Cheng Y; Han X; Wei Y; Wei X
Front Mol Biosci; 2021; 8():788440. PubMed ID: 34950704
[TBL] [Abstract][Full Text] [Related]
17. Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group.
Bila J; Katodritou E; Guenova M; Basic-Kinda S; Coriu D; Dapcevic M; Ibricevic-Balic L; Ivanaj A; Karanfilski O; Zver S; Beksac M; Terpos E; Dimopoulos MA
J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501388
[TBL] [Abstract][Full Text] [Related]
18. The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients.
Barankiewicz J; Szumera-Ciećkiewicz A; Salomon-Perzyński A; Wieszczy P; Malenda A; Garbicz F; Prochorec-Sobieszek M; Misiewicz-Krzemińska I; Juszczyński P; Lech-Marańda E
J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34207079
[TBL] [Abstract][Full Text] [Related]
19. Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.
Wang S; Li Z; Gao S
Biomark Res; 2021 Jun; 9(1):43. PubMed ID: 34090534
[TBL] [Abstract][Full Text] [Related]
20. Cereblon expression is a prognostic marker in newly diagnosed POEMS syndrome treated with lenalidomide plus dexamethasone.
Cai QQ; Gao XM; Le J; Zhao H; Cai H; Cao XX; Li J
Ann Hematol; 2021 Jun; 100(6):1547-1552. PubMed ID: 33839882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
